Modulating miR-21 signaling may work to reduce heart damage in people with pulmonary hypertension (PH), a preclinical study suggests.

Executives from Lexeo Therapeutics (NASDAQ:LXEO) outlined regulatory plans, clinical data, and manufacturing updates for its lead gene therapy programs during a presentation at Guggenheim’s 2026 ...

1 Division of Pediatric Cardiology, Department of Pediatrics and Adolescence Medicine, Medical University Graz, Graz, Austria 2 Division of Cardiology, Department of Medicine, Medical University Graz, ...

Introduction: Right ventricular (RV) dysfunction is associated with poor outcomes following mitral transcatheter edge-to-edge repair (M-TEER) in patients with severe mitral regurgitation (MR), yet the ...

Background The 12-lead ECG is a simple, inexpensive clinical tool with a key role in the assessment of patients with hypertrophic cardiomyopathy (HCM). The aims of this single centre, retrospective ...

A typical hypertensive heart disease phenotype is the left ventricular hypertrophy (LVH) and dysfunction, measurable via LV mass and global longitudinal strain. We aimed to evaluate the LV ...

Melatonin treatment improved quality of life and plasma antioxidant capacity in PAH patients, with significant symptom reductions in palpitations, dyspnea, and fatigue. The study involved 19 female ...

Introduction: In a model of right heart failure secondary to pulmonary artery banding (PAB), a mechanical approach using an elastic, biodegradable epicardial patch with integrated extracellular matrix ...

VEGFNP/SDFNP delivery reduced pulmonary arterial pressure, vascular resistance, and vessel thickening, nearly preventing right ventricular hypertrophy in PAH rats. The treatment increased eNOS ...